Navigation Links
Nutraceutical Reports Fiscal 2008 Q1 Results
Date:1/31/2008

PARK CITY, Utah, Jan. 31 /PRNewswire-FirstCall/ -- Nutraceutical International Corporation (Nasdaq: NUTR) today reported results for the fiscal 2008 first quarter ended December 31, 2007. Net sales for the fiscal 2008 first quarter were $41.1 million compared to $35.8 million for the same quarter of fiscal 2007. For the first quarter of fiscal 2008, net income was $3.2 million, or $0.28 diluted earnings per share, compared to net income of $3.4 million, or $0.30 diluted earnings per share, for the same quarter of fiscal 2007.

Bill Gay, chairman and chief executive officer, commented, "The growth in net sales of approximately 15% for the first quarter of fiscal 2008 compared to the same quarter of fiscal 2007 reflects the positive contributions of the six acquisitions completed during fiscal 2007. We remain focused on expanding our branded product sales through innovative marketing and sales programs that build long-term loyalty with our health and natural food store customers. Improved profitability and EBITDA from our acquisitions can normally be achieved within one to two years. Managing controllable expenses and gaining consolidation synergies from the fiscal 2007 acquired businesses will remain a dominant goal for the next few quarters. In spite of the current US economic slowdown, cost pressures and increasing competitive conditions, we remain confident in our business as we strive to serve our customers and take advantage of synergistic opportunities in the Healthy Foods Channel. We appreciate everyone that has helped us build a strong and successful business in the nutritional industry."

ABOUT NUTRACEUTICAL

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements
'/>"/>

SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
3. Nutraceutical Reports 2007 Fiscal Year End Results
4. New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs
5. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
6. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
7. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
8. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
9. Encision Reports Third Fiscal Quarter Results
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Amylin Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., ALEXANDRIA, Va., Jan. 8 /PRNewswire-USNewswire/ ... Organization along with several national leadersh...rding the principles of hospice care and protectio...ns standing together in sharing this unified messa...tion of Hospice and Palliative Medicine, Hospice a...
(Date:1/8/2009)..., California Assembly Member Tom Torlakson Introdu...swire-USNewswire/ -- Today, Lung Cancer Alliance...ember Tom Torlakson (D-11th District) for his cont...ing funding for lung cancer research. For the thi...ung cancer research is being considered in the Cal...
(Date:1/8/2009)...view says it lowered bad cholesterol more effectiv...lthDay News) -- After nearly a year of review, U.S...ed the continued use of the controversial choleste...Drug Administration said there was no significant ...ients taking Vytorin and patients taking the drug ...
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues Gr... IPC The Hospitalist Comp...spitalist physician group practice company, announ...ctice of Midwest Acute Care Consultants, Inc. (MAC...nts continued expansion in the St. Louis market, w...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2
...ational TB Control Programme (RNTCP) aims at widen...uality treatment and diagnostic services to all tu...0 % of HIV-positive people are more prone to contr...amily Welfare Minister Anbumani Ramadoss plan to t...
...nducted by Steven M. Kurtz, of Exponent Inc., a Ph...ting firm//, there is an increase in demand for ar...artificial joints needed to replace damaged knees ...e study showed that the demand for artificial hips...
...ts had captured the market and minds of various pe...iny. // A number of detox products are to be inve... report by the BBC which drew its attention to som...he Medical Health Care Products Regulatory Agency ...
...ar, Nitish Kumar assured that the Bihar Government...ing spread of AIDS/HIV in the state //, addressing...ma foundation, Samyak and the National Aids Contro...oncern over the explosive prevalence of HIV/AIDS i...
Other Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2
(Date:1/8/2009)...o, Jan. 8 IntelligentMDx a develope...ays, today announced that verification studies of ... complete. , , Under the verification protocol...d reproducibility and robustness of the BK Viral Q... agreed with internally generated analytical perfo...
(Date:1/7/2009)...re-FirstCall/ -- Eli Lilly and Company,(NYSE: L...esponse letter from,the U.S. Food and Drug Admini...on (LAI) for acute and maintenance treatment of sc...k with the agency on the new drug,application (ND...al clinical trials for the continued,review of th...
(Date:1/7/2009)...rease , , WHITE PLAINS, N.Y., Jan. 7 /PRNewswir... that the decades-long rise in the United States p...than ever at increased risk of death and disabilit...43,000 babies were born too soon in 2006, accordin...ich today released "Births: Final data for 2006," ...
(Date:1/7/2009)...opment Based On Osteotech,s Proprietary Human Coll...on; FDA Filing Anticipated in Third Quarter 2009 ...ll/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lead...regenerative healing, announced today that it has ...h(TM) BioRegeneration Matrix. The first five patie...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Preterm Births Rise 36 Percent Since Early 1980s 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 1MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 2Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 1Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 1Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 3Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 1Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 2Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 3Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 5Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 6Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 7
...ently approved by FDA for long-term maintenance,tr...ate first,nebulized formoterol fumarate provides i...moterol, enhanced patient quality of,life, and pos...7 /PRNewswire/ -- Data presented at the,Internatio...TS),demonstrate that Perforomist (formoterol fumar...
...ivolol Lowers Blood Pressure in Obese and,Non-Obes...Newswire-FirstCall/ -- Forest,Laboratories, Inc. t...dies and one pooled analysis of nebivolol, a selec...urrently under review by,the U.S. Food and Drug Ad...on. Data from the two clinical studies show that,n...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
2.5 mm cups angled 50 degrees, 10 mm from angle to tip. Serrated handle with polished finish.
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish.
Puntenney curved forceps, curved, smooth 10 mm platforms.
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms.
Medicine Products: